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Abstract: Authors present a retrospective study of 427 patients with brain metastases 
admitted and treated in third and fourth neurosurgical departments of Emergency 
Clinical Hospital “Bagdasar-Arseni” Bucharest, from January, 2005 until December, 
2014. 62.1% of all patients were men and 37.9% were women, with a medium age of 56.8 
years, ranging between 17 and 85 years. 311 patients (72.8%) had a single metastasis, 79 
patients (18.5%) developed 2 or 3 metastases and 37 patients (8.7%) had more than 3 
metastases. The biggest four metastases in multiple cases were noted in database 
regarding location, either reported to left / right hemisphere, either related to site (frontal 
parietal etc.), and dimensions. In the case of malignant melanoma (22 men and 24 
women) the status of the primary tumor was noted: the malignant melanoma was 
operated in 32 cases (69.6%) and in 7 patients (15.2%) the primary tumor was not 
operated. In another 7 cases the status of the primary tumor was not noted. The most 
frequent location for malignant melanoma was the legs in women and anterior thorax in 
men. In conclusion, cerebral metastases from malignant melanoma have most frequent 
intratumoral hemorrhages, comparative with other primary sources. Common primary 
sites founded in this study is legs in women and anterior thorax in men. Treatment of 
cerebral metastases is complex, multimodal, implying neurosurgeons, oncologists and 
radiotherapists. 
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Introduction 
Brain metastases are the most frequent 
cerebral tumors and represent the main cause 
for morbidity and mortality among patients 
with systemic cancer. Between 20 – 40% of 
patients develop one or more brain metastases 
during neoplastic disease. The most of the 
brain metastases arise from lung cancer, breast 
cancer, malign melanoma and kidney cancer. 
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All studies report a maximum incidence in 
sixth and seventh decades of life. Among all 
systemic cancer, malign melanoma has the 
greatest propensity for brain metastases. 
Modern treatment for brain metastases 
includes currently not only whole brain 
radiotherapy, but more complex approach, 
consisting in classic surgery, stereotactic 
radiosurgery and chemotherapy.  
Surgical resection represents the gold 
standard for brain metastases therapy, because 
it provides local control of diseases, releases 
the symptoms and accurate establish 
histopathological diagnosis. Unfortunately, 
not all patients with brain metastases are good 
candidates for surgical treatment. 
Material and methods 
Authors present a retrospective study of 
427 patients with brain metastases admitted 
and treated in third and fourth neurosurgical 
departments of Emergency Clinical Hospital 
“Bagdasar-Arseni” Bucharest, from January, 
2005 until December, 2014. Clinical data were 
collected from clinical observation sheets and 
surgical protocols recorded for each patient, 
including demographic data (age, sex), 
symptoms, Karnofsky Performance Scale, 
number and location of tumors, systemic 
disease, imaging, surgical treatment and 
outcome. Furthermore, location of primary 
cancer was noted for malign melanoma, as 
well as the presence of intratumoral 
hemorrhage visible on CT or MRI scan. 
Results 
62.1% of all patients were men and 37.9% 
were women, with a medium age of 56.8 years, 
ranging between 17 and 85 years. 
Demographic data are shown in table 1, figure 
1. The maximum incidence of brain 
metastases was observed in sixth and seventh 
decades of life, 35.4% and 30.7% respectively, 
as it is shown in table 1, figure 2. 
 
 
Figure 1 - Sex distribution 
 
 
Figure 2 - Histogram from age distribution 
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311 patients (72.8%) had a single 
metastasis, 79 patients (18.5%) developed 2 or 
3 metastases and 37 patients (8.7%) had more 
than 3 metastases. The biggest four metastases 
in multiple cases were noted in database 
regarding location, either reported to left / 
right hemisphere, either related to site (frontal 
parietal etc.), and dimensions. In 70.3% of 
cases (300 patients) tumors were located 
supratentorial, and in 18.5% (79 patients) 
brain metastases were located infratentorial. 
Both supra- and infratentorial location was 
seen in 11.2% of cases (48 patients) (Figure 3). 
The medium size of the largest metastasis 
was 31.6 mm (varying from 4 to 80 mm). The 
medium size for the second metastasis was 
10.6 mm, 9 mm for third tumor and 8.9 mm 
for fourth tumor. 
Lung cancer was the starting point for 
brain metastases in almost half of the cases 
(196 patients, 45.9%), and most of them were 
men (84.7%). Next source for brain metastases 
was breast cancer (68 patients, 15.9%) 95.6% of 
the patients with breast cancer were women 
and 4.4% were men (3 patients). The third 
starting point for cerebral metastases was 
malignant melanoma (46 patients, 10.8%). 
Other primary sites were noted: colon cancer 
(24 patients), kidney cancer (19 patients), 
ovarian cancer (8 patients), cervix cancer (7 
cases), and prostate cancer (4 cases). In 40 
patients (9.4%) the investigations failed to 
reveal the source for brain metastases (Table 2, 
Figure 4). 
 
 
Figure 3 - Location of cerebral metastasis 
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TABLE 1 
Characteristics of patients with cerebral metastasis 
Characteristic of patients with brain metastasis Count 
Sex M 265 (62.1%) 
F 162 (37.9%) 
Age <20 years 3 (0.7%) 
21-30 years 6 (1.4%) 
31-40 years 27 (6.3%) 
41-50 years 72 (16.9%) 
51-60 years 151(35.4%) 
61-70 years 131(30.7%) 
71-80 years 33 (7.7%) 
>81 years 4 (0.9%) 
   
Number of brain metastases 1 311 (72.8%) 
2 50 (11.7%) 
3 29 (6.8%) 
>3 37 (8.7%) 
   
Location Supratentorial 300 (70.3%) 
Infratentorial 79 (18.5%) 
Supra/Infratentorial 48 (11.2%) 
   
Intracranial hypertension  402 (94.6%) 
Neurological deficits Hemiparesis 130 (30.7%) 
Hemiplegia 28 (6.6%) 
Seizures Generalized seizures 51 (12.0%) 
 Focal seizures 45 (10.6%) 
Facial nerve palsy  24 (5.6%) 
Cranial nerve palsies  36 (8.5%) 
Aphasia Broca’s aphasia 46 (10.8%) 
 Werniche’s aphasia 16 (3.8%) 
 Dyshartria 14 (3.3%) 
   
Memory disorders  41(9.6%) 
Visual problem  49 (11.5%) 
Personality disorders  36 (8.5%) 
Confusion  34 (8.0%) 
Bone metastasis  17 (4.0%) 
Lung metastasis  38 (8.9%) 
Liver metastasis  18 (4.2%) 
Kidney metastasis  5 (1.2%) 
Genital metastasis  10 (2.3%) 
Adrenal metastasis  9 (2.1%) 
Other organs  11 (2.6%) 
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TABLE 2 
Primary site of cancer 
 TOTAL PACIENTS MASCULIN FEMININ 
Lung cancer 196 (45.9%) 166 (84.70%) 30 (15.30%) 
Breast cancer 68 (15.9%) 3 (4.4%) 65 (95.6%) 
Melanoma malign 46 (10.8%) 22 (47.8%) 24 (52.2%) 
Kidney cancer 19 (4.4%) 15 (78.9%) 4 (21.1%) 
Colon cancer 24 (5.6%) 15 (62.5%) 9 (37.5%) 
Unspecified cancer 1 (0.2%) 1 (100%) 0 (0%) 
Prostate cancer 4 (0.9%) 4 (100%) 0 (0%) 
Ovary cancer 8 (1.9%) 0 (0%) 8 (100%) 
Unknown cancer 40 (9.4%) 30 (75%) 10 (25%) 
Sarcoma 2 (0.5%) 1 (50%) 1 (50%) 
Laryngeal cancer 2 (0.5%) 2 (100%) 0 (0%) 
Uterine cancer 7 (1.6%) 0 (0%) 7 (100%) 
Bladder cancer 2 (0.5%) 2 (100%) 0 (0%) 
Mediastinal cancer 2 (0.5%) 2 (100%) 0 (0%) 
Malignant timoma 1 (0.2%) 0 (0%) 1 (100%) 
Testicular cancer 1 (0.2%) 1 (100%) 0 (0%) 
Gastric cancer 3 (0.7%) 1 (33.3%) 2 (66.7%) 
Thyroid cancer 1 (0.2%) 0 (0%) 1 (100%) 
Total 427 (100.0%) 265 (62.1%) 162 (37.9%) 
 
  
 
 
 
Pruna, Gorgan          Particular aspects of cerebral metastases secondary to malignant melanoma 
 
 
 
 
 
 
 
 
Figure 4 - Primary site 
 
 
Figure 5 - Differences in symptomatology between patients with single metastasis and patients with multiple metastases 
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patients) and 22.6% of patients presented with 
seizures. Altered consciousness was 
encountered in 34 cases (8%), with giant 
metastases or posterior cranial fossa locations 
(Figure 5). Differentiated analysis of patients 
with one vs multiple metastases failed to reveal 
any statistical significant difference regarded 
to symptomatology (p=0.99), as shown in 
figure 5. 
In the case of malignant melanoma (22 
men and 24 women) the status of the primary 
tumor was noted: the malignant melanoma 
was operated in 32 cases (69.6%) and in 7 
patients (15.2%) the primary tumor was not 
operated. In another 7 cases the status of the 
primary tumor was not noted. The most 
frequent location for malignant melanoma 
was the legs in women and anterior thorax in 
men, as shown in figure 6. 
Cerebral imaging (CT or MRI scan with 
and without contrast enhancement) revealed 
intratumoral hemorrhage in 13 cases of brain 
metastases secondary to malignant melanoma, 
which meant the highest incidence, followed 
by cerebral metastases from lung cancer, with 
3 cases of intratumoral hemorrhage (Figure 7). 
 
 
Figure 6 - Location of malign melanoma 
 
  
  
Figure 7 - MRI aspect of intratumoral hemorrhage 
(brain metastases from malignant melanoma) 
 
All patients received steroids, while 
anticonvulsants were administrated in 
patients with supratentorial metastases. 335 of 
all patients (79.2%) underwent surgery for 
brain metastases. Surgical resection was 
performed in 34 of all patients diagnosed with 
malignant melanoma (73.9%), while surgery 
was not considered an option in 4 patients 
with multiple brain metastases, who had a 
poor biologic status. 1 patient refused surgery 
and was referred to oncologist. 8 patients 
underwent stereotactic gamma-knife 
radiosurgery. 
Most patients had a good postoperative 
outcome. Only in 6.8% of cases the neurologic 
status worsened. The most common 
postoperative complication was cerebral 
hematoma, encountered in 17 patients (4.7%).  
Worsening of motor and sensitive deficits was 
noted in 8 cases (2.2%). 7 patients were 
complicated with pneumonia and 1 patient 
developed pulmonary embolism. 
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Discussions 
Cerebral metastases are the most frequent 
tumors of the brain. They arise mainly from 
lung cancer (50%), breast cancer (15-20%), 
malignant melanoma (5-20%), and colon and 
kidney cancer (1, 2). Common clinical 
manifestations derive from raising of the 
intracranian pressure, focal neurologic 
deficits, seizures and altered consciousness. 
Occurrence of brain metastases 
dramatically lowers the survival rate. If 
untreated, medium survival is approximately 
one month. Corticotherapy increase survival 
at 2 months (3). Association of corticotherapy 
with whole brain radiotherapy increase 
survival at 3 to 6 months (4-7). Surgical 
resection of the tumors raise life expectancy at 
9 – 14 months, depending of primary cancer, 
Karnofsky Performance Scale, presence or 
absence of other systemic metastases (6-10). 
Major changes in the treatment for brain 
metastases had seen over time. The main goals 
of the treatment are lowering morbidity and 
mortality, with improvement of quality of life. 
Corticotherapy relief symptomatology by 
reducing peritumoral edema (11, 12). All 
patients in this study received steroids 
(dexamethasone sodium phosphate 8 mg 
daily). Surgical treatment is usually indicated 
in patients with Karnofsky Performance Scale 
> 70, with a single brain metastasis, which can 
be approached such that no additional motor 
or sensitive deficit be caused postoperative. 
Cerebral metastases are usually well 
demarcated form surrounding cerebral tissue. 
The 3 main goals of the surgical treatment are 
establishing of accurate histologic diagnosis, 
quick relief of symptoms and local cure of 
disease. Modern surgery, using of 
microsurgical techniques, neuronavigation 
and intraoperative monitoring had lead today 
to drops of intra- and postoperative 
complications (13, 14) and dramatically 
decreased immediate postoperative mortality 
under 1% (15).  Patchell, Tibbs, 1990 (7) 
showed that surgical resection of brain 
metastases increases survival in comparison 
with whole brain radiotherapy alone (7). 
Furthermore, whole brain radiotherapy after 
surgical removal reduces the risk of recurrence 
compared with surgery alone (16). 
Stereotactic radiosurgery (SRS), used since 
1980 in North America (17) revolutionized 
treatment for cerebral metastases and not only. 
In the present, prospective randomized studies 
shows that, for selected cases, with 3 or 4 brain 
metastases, smaller than 2 cm, stereotactic 
radiosurgery combined with whole brain 
radiotherapy increase survival in comparison 
with WBRT alone (18, 19). Stereotactic 
radiosurgery has several advantages, such as: it 
is easily tolerated by patients, can treat deep 
sites or tumors located in eloquent areas, that 
cannot be approached surgical, and may be 
tried in treatment of some cerebral metastases 
considered radioresistant, such as those 
derived from malignant melanoma and kidney 
cancer (20).   Postoperative radiation has the 
main goal to destroy residual tumoral cells 
from tumor bed or other occult locations. 
Patchell et all showed that when surgical 
treatment were applied alone, without WBRT, 
tumor recurred in medium in 27 weeks after 
surgery in 46% of patients, in whom complete 
surgical resection was confirmed on MRI. 
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Postoperative WBRT decreased recurrence at 
10% and prolonged time of recurrence over 52 
weeks (16).  
Conclusions 
Cerebral metastases from malignant 
melanoma have most frequent intratumoral 
hemorrhages, comparative with other primary 
sources. Common primary sites founded in 
this study is legs in women and anterior thorax 
in men. Treatment of cerebral metastases is 
complex, multimodal, implying 
neurosurgeons, oncologists and 
radiotherapists. Surgical resection combined 
with postoperative radiotherapy (WBRT or 
SRS) represent the gold standard of treatment 
for brain metastases. In cases of multiple brain 
metastases, the particular metastasis which is 
responsible of main symptomatology has 
surgical priority and should be resect first. 
References 
1.Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, 
Lai P, Sawaya RE. Incidence proportions of brain 
metastases in patients diagnosed (1973 to 2001) in the 
Metropolitan Detroit Cancer Surveillance System. 
Journal of clinical oncology: official journal of the 
American Society of Clinical Oncology. 
2004;22(14):2865-72. 
2.Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. 
Incidence of brain metastases in a cohort of patients with 
carcinoma of the breast, colon, kidney, and lung and 
melanoma. Cancer. 2002;94(10):2698-705. 
3.Ruderman NB, Hall TC. Use of Glucocorticoids in the 
Palliative Treatment of Metastatic Brain Tumors. Cancer. 
1965;18:298-306. 
4.Cairncross JG, Kim JH, Posner JB. Radiation therapy for 
brain metastases. Annals of neurology. 1980;7(6):529-41. 
5.Kurtz JM, Gelber R, Brady LW, Carella RJ, Cooper JS. 
The palliation of brain metastases in a favorable patient 
population: a randomized clinical trial by the Radiation 
Therapy Oncology Group. International journal of 
radiation oncology, biology, physics. 1981;7(7):891-5. 
6.Sause WT, Crowley JJ, Morantz R, Rotman M, Mowry 
PA, Bouzaglou A, et al. Solitary brain metastasis: results 
of an RTOG/SWOG protocol evaluation surgery + RT 
versus RT alone. American journal of clinical oncology. 
1990;13(5):427-32. 
7.Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, 
Maruyama Y, Kryscio RJ, et al. A randomized trial of 
surgery in the treatment of single metastases to the brain. 
The New England journal of medicine. 1990;322(8):494-
500. 
8.Sundaresan N, Galicich JH. Surgical treatment of brain 
metastases. Clinical and computerized tomography 
evaluation of the results of treatment. Cancer. 
1985;55(6):1382-8. 
9.Galicich JH, Sundaresan N, Arbit E, Passe S. Surgical 
treatment of single brain metastasis: factors associated 
with survival. Cancer. 1980;45(2):381-6. 
10.Burt M, Wronski M, Arbit E, Galicich JH. Resection of 
brain metastases from non-small-cell lung carcinoma. 
Results of therapy. Memorial Sloan-Kettering Cancer 
Center Thoracic Surgical Staff. The Journal of thoracic 
and cardiovascular surgery. 1992;103(3):399-410; 
discussion -1. 
11.Vecht CJ, Hovestadt A, Verbiest HB, van Vliet JJ, van 
Putten WL. Dose-effect relationship of dexamethasone 
on Karnofsky performance in metastatic brain tumors: a 
randomized study of doses of 4, 8, and 16 mg per day. 
Neurology. 1994;44(4):675-80. 
12.Wolfson AH, Snodgrass SM, Schwade JG, Markoe 
AM, Landy H, Feun LG, et al. The role of steroids in the 
management of metastatic carcinoma to the brain. A pilot 
prospective trial. American journal of clinical oncology. 
1994;17(3):234-8. 
13.Black PM, Johnson MD. Surgical resection for patients 
with solid brain metastases: current status. Journal of 
neuro-oncology. 2004;69(1-3):119-24. 
14.Paek SH, Audu PB, Sperling MR, Cho J, Andrews DW. 
Reevaluation of surgery for the treatment of brain 
metastases: review of 208 patients with single or multiple 
brain metastases treated at one institution with modern 
neurosurgical techniques. Neurosurgery. 
2005;56(5):1021-34; discussion -34. 
15.Sawaya R, Hammoud M, Schoppa D, Hess KR, Wu SZ, 
Shi WM, et al. Neurosurgical outcomes in a modern series 
of 400 craniotomies for treatment of parenchymal 
  
 
 
 
Pruna, Gorgan          Particular aspects of cerebral metastases secondary to malignant melanoma 
 
 
 
 
 
 
 
tumors. Neurosurgery. 1998;42(5):1044-55; discussion 
55-6. 
16.Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, 
Mohiuddin M, Kryscio RJ, et al. Postoperative 
radiotherapy in the treatment of single metastases to the 
brain: a randomized trial. Jama. 1998;280(17):1485-9. 
17.Pike B, Peters TM, Podgorsak E, Pla C, Olivier A, de 
Lotbiniere A. Stereotactic external beam calculations for 
radiosurgical treatment of brain lesions. Applied 
neurophysiology. 1987;50(1-6):269-73. 
18.Andrews DW, Scott CB, Sperduto PW, Flanders AE, 
Gaspar LE, Schell MC, et al. Whole brain radiation 
therapy with or without stereotactic radiosurgery boost 
for patients with one to three brain metastases: phase III 
results of the RTOG 9508 randomised trial. Lancet. 
2004;363(9422):1665-72. 
19.Kondziolka D, Patel A, Lunsford LD, Kassam A, 
Flickinger JC. Stereotactic radiosurgery plus whole brain 
radiotherapy versus radiotherapy alone for patients with 
multiple brain metastases. International journal of 
radiation oncology, biology, physics. 1999;45(2):427-34. 
20.Muacevic A, Kreth FW, Mack A, Tonn JC, Wowra B. 
Stereotactic radiosurgery without radiation therapy 
providing high local tumor control of multiple brain 
metastases from renal cell carcinoma. Minimally invasive 
neurosurgery : MIN. 2004;47(4):203-8. 
 
 
 
